Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with improved gross margins and sustainable volume growth. Management is confident in achieving the ASP increase, and the strategic expansion of territories and pipeline developments are promising. Despite some increase in operating expenses and net loss, the company is on track for positive adjusted EBITDA and free cash flow. The Q&A section supports the positive outlook, highlighting market potential and strategic initiatives. While management avoided specific guidance on volume, the overall sentiment remains positive with expectations of continued growth.
Key Financial Performance
Revenue Q2 revenue was $17.2 million, representing a 14% year-over-year growth. This growth was driven by an increase in test volume, which was up 14% sequentially from Q1 and 7% from Q2 2024, as well as continued ASP (Average Selling Price) expansion.
Gross Margin Gross margin in Q2 was just over 60%, up from about 59% in Q1 and 60% in Q2 2024. This improvement reflects the growing contribution of higher ASP and normalization of lab operations following Q1 investments.
Operating Expenses Operating expenses for Q2 were $13 million, up from $12.5 million in Q1 and $11.6 million in Q2 2024. The increase was due to one-time expenses, continued investment in R&D, clinical studies, pipeline advancement, and strategic additions to the commercial team.
Net Loss Net loss for Q2 was $4.4 million compared to $3 million in Q2 2024. The increase was driven by the impact of the new debt facility, which added $600,000 in noncash interest and fair value adjustments, $300,000 for loss on debt extinguishment, and $400,000 in cash interest expense.
Adjusted EBITDA Loss Adjusted EBITDA loss was $1.7 million in Q2 compared to $1.6 million in Q2 2024. The company is focused on achieving positive adjusted EBITDA in the foreseeable future.
Cash and Equivalents The company ended Q2 with $30 million in cash, cash equivalents, and restricted cash. Operating cash burn for Q2 was just under $3 million, positioning the company to be at or near free cash flow positive in the second half of 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Biomarker Launch: The addition of novel T cell and RA markers has been a meaningful catalyst in commercial conversations, with enthusiasm from clinicians for new science in a field with little innovation in the past 50 years.
AVISE CTD Test: The test volume growth was substantial, achieving the best quarterly volume since strategic adjustments in 2023. It has been instrumental in diagnosing complex cases, such as seronegative RA and ANA-negative lupus nephritis.
Pipeline Advancements: Efforts to expand serum-negative offerings with anti-PAD4 biomarkers are progressing, with a planned submission to the New York State Department of Health in August and a commercial launch expected in 2026.
Territory Revenue Growth: Average revenue per territory reached over $430,000, a 50% increase since 2023, driven by organic growth and clinical recognition of differentiated science.
Physician Base Expansion: Growth is driven by increased ordering within the existing physician base and onboarding of new physicians.
Revenue Growth: Q2 revenue reached $17.2 million, a 14% year-over-year increase, marking the highest quarterly revenue in company history.
Gross Margin Improvement: Gross margin improved to just over 60%, driven by higher ASP and normalization of lab operations.
Financial Position: Ended Q2 with $30 million in cash and equivalents, with a clear path to positive operating cash flow by the second half of 2025.
Leadership Additions: Dr. Michael Mahler joined as Chief Scientific Officer, bringing over two decades of R&D experience, and Chas McKhann joined the Board of Directors, adding strategic expertise.
R&D Investments: Significant progress in lupus nephritis diagnostics and novel blood-based biomarkers of kidney damage, with ongoing validation studies and potential for future partnerships.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue growth dependency: The company's revenue growth is heavily reliant on the successful adoption of its biomarkers and diagnostic tools. Any delays in reimbursement strategies or challenges in physician adoption could adversely impact financial performance.
Debt and financial flexibility: The company has refinanced its debt and added new credit facilities, but this increases financial obligations. Rising interest expenses and potential challenges in managing debt could strain cash flow and profitability.
R&D investment risks: Significant investments in R&D, including new hires and clinical studies, are critical for future growth. However, these investments may not yield expected results, leading to financial strain.
Regulatory hurdles: The company plans to submit validation packages for new biomarkers to regulatory bodies. Delays or rejections in regulatory approvals could hinder product launches and revenue growth.
Market competition: The autoimmune diagnostics market is competitive. Failure to differentiate products or respond to competitors' innovations could impact market share and revenue.
Operational scalability: The company is expanding its commercial team and operations. Inefficiencies or challenges in scaling operations could lead to increased costs and reduced profitability.
Economic uncertainties: Broader economic conditions, such as changes in healthcare spending or patient deductibles, could impact revenue collection and financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: Exagen Inc. provided full-year revenue guidance of between $65 million and $70 million for 2025. At the high end of this range, the company expects to achieve positive adjusted EBITDA in Q4 2025 and sustain it throughout 2026.
Revenue Growth: The company expects over 17% revenue growth in 2025, driven by increased test volumes, ASP expansion, and new biomarker contributions.
Gross Margin Expansion: Gross margins are expected to continue expanding throughout 2025, primarily due to ASP improvements and normalization of lab operations.
Operating Expenses: Operating expenses are expected to remain at current levels for the remainder of 2025, with modest increases over time in absolute dollars as the company scales. However, these expenses are expected to decline as a percentage of revenue, reflecting growing operating leverage.
Biomarker Launches: The company plans to launch the anti-PAD4 biomarker commercially heading into 2026, with clinical and analytical validation submission to the New York State Department of Health expected in August 2025.
Lupus Nephritis Diagnostics: Exagen is advancing its urine and blood-based lupus nephritis diagnostics, with strategies to secure reimbursement and unlock additional pharma partnerships.
Kidney Damage Biomarkers: Efforts to discover novel blood-based biomarkers for kidney damage are progressing, with potential for standalone value or combination with urine-based platforms.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How sustainable is the 7% volume growth achieved this quarter, and what factors contributed to it?
A:The growth is attributed to the strong team, with about 1/4 to 1/3 of the team being new in the last 12 months, gaining confidence and familiarity with the product and processes. The new markers also served as a catalyst. The company believes the growth is sustainable due to a large market with only 10% penetration and expects further results from sales force expansion later in the year.
Q:Is the $90 increase in ASP for the trailing 12-month period still achievable by the end of 2025?
A:Management is bullish on achieving the $90 increase, though the pace of climb is difficult to forecast. Adjustments were made to accrual rates in Q2 to align closer to cash collection, and the company remains confident in achieving or exceeding the $90 target.
Q:What step-down in volume is expected in Q3 and Q4, and how does the company plan to address seasonality?
A:The company does not guide volume on a quarterly basis but expects traditional seasonality in the back half of the year. However, sales force expansion is anticipated to counteract this, and the aim is to continue growing.
Q:Will the launch of new tests in the next 6-12 months impact ASP, and what is the pipeline strategy?
A:The launch of two additional markers for seronegative RA is expected to be a tailwind to ASP, though not as significant as the $90 impact from January's launch. The pipeline includes lupus nephritis markers for diagnosis and prognosis, with a focus on Medicare reimbursement before commercial launch. The company is also exploring biomarkers for disease activity in RA and lupus.
Q:What is the progress and outlook for the biopharma business?
A:The biopharma business has grown from a few hundred thousand dollars annually to $100,000-$300,000 per quarter. The company is strengthening relationships with collaborators and expects this to be a contributing factor in the second half of the year. The business is margin accretive and helps de-risk R&D development.
Q:What are the company’s efforts and plans for territory expansion?
A:The company started the year with 40 territories, expanded to 42 in Q2, and expects to reach 44-45 by year-end. Future expansion will be based on empirical data and market dynamics, with a focus on large metropolitan areas like Manhattan.
Q:What levers can be pulled to further increase ASPs beyond the $90 increase?
A:The company is focusing on appeals efforts, revenue cycle improvements, and engaging with major payers to drive ASPs higher. The current blended ASP is $428, with significant room for improvement towards the clinical lab fee schedule rate of $1,299.
Q:What market access initiatives are in place to drive volume growth and increase penetration?
A:The company is running digital marketing campaigns, conducting clinical research, and partnering with KOLs to validate and promote new markers. Training the sales team to handle clinical questions effectively is also a key focus.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance on quarterly volume expectations for Q3 and Q4, citing traditional seasonality and sales force expansion as factors but not offering clear numerical forecasts. Additionally, while discussing the pipeline strategy, management did not provide specific timelines or financial projections for the lupus nephritis markers or other pipeline efforts.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACR SLE
ANA BCd
ANA suspicion
ASP adoption
AVISE example
AVISE practice
Aballi CEO
Aballi President
Alexander Mikson
Arizona San
BCd cell
RA marker
RD
Research Division
San Diego
blood
cell marker
diagnosis AVISE
diagnostics
engagement
field biomarker
follow
hospital
kidney
leader
lupus nephritis
marker patient
pain
profile
proteinuria
science
steroid
strength
urine
XGN Transcript
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Unknown5-12
The earnings call presents a mixed picture: revenue declined 5% YoY, but gross margin improved to 65%. Despite a net loss, operational efficiencies reduced expenses by 8%. Revenue growth of 10-15% is expected, with a focus on new products and market expansion. However, lack of discussion on risks and returns, along with unclear Q&A responses, suggests caution. Overall, the sentiment is neutral, with no strong catalysts for significant stock movement.
Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript
Unknown3-10
The earnings call presents a mixed outlook. While there is strong volume growth and positive trends in market expansion, the delay in profitability targets and ASP challenges weigh negatively. The Q&A reveals management's cautious stance on profitability timelines and ASP, which adds uncertainty. However, the company's strategic investments and potential ASP improvements, alongside strong relationships with ACR, provide a balance. Without market cap data, a neutral prediction (-2% to 2%) is reasonable, reflecting both positive growth aspects and financial uncertainties.
Exagen Inc. (XGN) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call summary suggests mixed signals: positive revenue growth and ASP expansion are countered by challenges in achieving ASP targets and addressing payment denials. The Q&A section reveals management's unclear responses on key metrics, raising concerns. However, the strategic plan for 2025 shows optimism with new biomarker launches and potential pharma partnerships. Overall, the sentiment is balanced, leading to a neutral prediction for stock price movement over the next two weeks.
Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript
Positive7-29
The earnings call reveals strong financial performance with improved gross margins and sustainable volume growth. Management is confident in achieving the ASP increase, and the strategic expansion of territories and pipeline developments are promising. Despite some increase in operating expenses and net loss, the company is on track for positive adjusted EBITDA and free cash flow. The Q&A section supports the positive outlook, highlighting market potential and strategic initiatives. While management avoided specific guidance on volume, the overall sentiment remains positive with expectations of continued growth.
XGN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
